| 1 |
Development of innovative therapeutics that dually protect against bone erosion and inflammatory arthritis |
| Antibody |
Rheumatoid Arthritis |
Integrin αvβ3/Siglec.15 |
Preclinical |
MedPacto, Inc. |
RS-2023-00282595 |
|
| 2 |
Development of a novel topical treatment for atopic dermatitis by modulating TSLP signaling |
| Small Molecules |
Atopic dermatitis |
TSLP/TSLPR |
Preclinical |
AmtixBio |
RS-2023-00258738 |
|
| 3 |
Development of BFD1R, an immunomodulatory Live Biotherapeutic Products(LBP) for rheumatoid arthritis |
| Others |
Rheumatoid Arthritis |
Gut (Gut.joint axis |
Preclinical |
BIFIDO Co., Ltd |
RS-2023-00258617 |
|
| 4 |
Completion of non-clinical studies and IND authorization for a 3rd generation multiple sclerosis drug candidate based on biased modulation that overcomes the limitations of cardiac side effects |
| Small Molecules |
Multiple Sclerosis |
S1P1 |
Preclinical |
CUREVERSE |
RS-2023-00217346 |
|
| 5 |
Non-clinical study of IBD using Live Microbial Gene Therapy based on recombinant microbial Toolbox |
| Gene Therapy |
Ulcerative colitis |
VIP |
Preclinical |
Liveome Inc. |
RS-2023-00217138 |
|
| 6 |
Clinical development of a novel synthetic AHR agonist PB542 as an IBD therapeutics |
| Small Molecules |
Crohn's disease |
AhR |
Preclinical |
Parenchyma Biotech |
RS-2022-00165759 |
|
| 7 |
Multi-functional immune-modulating antibody therapeutics for autoimmune disease |
| Antibody |
Rheumatoid Arthritis, Autoimmune Disease |
OX40L, TNF-α |
Preclinical |
IMBiologics |
HN22C0229 |
|
| 8 |
Nonclinical Study for Treatment of IRI Using Bilirubin Nanoparticle (Brixelle) |
| Others |
Ischemia reperfusion injury |
ROS |
Preclinical |
BILIX |
HN21C0947 |
|
| 9 |
Development of Complement C5-inhibiting antibody for Autoimmune diseases |
| Antibody |
Paroxysmal nocturnal hemoglobinuria |
C5 |
Preclinical |
ImmunAbs |
HN21C0649 |
|
| 10 |
Development of a therapeutic agent for ulcerative colitis by regulating glycogen metabolism of immune cells and intestinal epithelial cells |
| Small Molecules |
Ulcerative colitis |
PYGL |
Preclinical |
INNOVO Therapeutics |
HN21C0604 |
|
